What Does Fluconazole Treat? Fungal and Yeast Infections

Fluconazole is an antifungal medication used to treat a wide range of infections caused by fungi, most commonly yeast in the genus Candida. Its best-known use is a single 150-milligram capsule for vaginal yeast infections, but the drug’s reach extends much further: bloodstream Candida infections, cryptococcal meningitis, certain lung fungi, and even fungal nail infections. What makes fluconazole unusual among antifungals is how easily it spreads through the body, including into the brain and spinal fluid, and how well it is tolerated by mouth.

How Fluconazole Works

Fungal cells need a molecule called ergosterol to keep their outer membranes intact, much the way human cells rely on cholesterol. Fluconazole blocks a specific enzyme involved in making ergosterol. When that enzyme is shut down, ergosterol disappears from the fungal membrane and gets replaced by toxic byproducts that make the membrane leaky and unstable.¹ The fungus can no longer hold itself together, and the immune system finishes it off. Human cells do not use ergosterol, which is why fluconazole can attack fungi without doing much harm to the patient’s own tissues.

Vaginal Yeast Infections

This is the condition most people associate with fluconazole. A single oral dose of 150 mg is the standard treatment, and it works remarkably well for uncomplicated cases. In one multicentre trial of 180 women with confirmed vaginal candidiasis, about 97 percent were cured or markedly improved within five to sixteen days of a single dose, and roughly 88 percent remained cured at longer follow-up.² The convenience of one pill rather than a week of topical creams is a major reason fluconazole became one of the most prescribed antifungals in the world.

For women who get recurrent yeast infections (four or more episodes a year), doctors sometimes prescribe a lower dose of fluconazole taken weekly for several months as suppressive therapy. The drug’s long half-life in the body makes this kind of schedule practical.

Bloodstream Candida Infections

When Candida enters the bloodstream, the situation becomes far more serious than a surface-level yeast infection. Candidemia is one of the most common hospital-acquired bloodstream infections, and it carries a high mortality rate. Fluconazole has been a front-line treatment for invasive candidiasis since 1990 and remains a first-line option when the Candida species involved is known to be susceptible.³

In practice, however, many hospitals now start patients on a different class of antifungal called echinocandins because these drugs cover a broader range of Candida species, including some that are resistant to fluconazole. Once lab results confirm the species and show it responds to fluconazole, doctors frequently switch the patient over. A post-hoc analysis of three cohort studies found that stepping down from an echinocandin to fluconazole within the first five days was safe in patients whose infections were caused by fluconazole-susceptible strains, as long as the source of infection was controlled and the patient was hemodynamically stable.⁴ This stepdown strategy matters because fluconazole can be given by mouth and taken at home, while echinocandins require intravenous infusion in a hospital.

A pivotal trial comparing anidulafungin (an echinocandin) head-to-head against fluconazole found that anidulafungin had a higher success rate at the end of intravenous therapy, roughly 76 percent versus 60 percent.⁵ That gap explains why echinocandins are now preferred as initial therapy. But fluconazole remains valuable as oral stepdown treatment and as a first choice in settings where echinocandins are unavailable. Even for Candida glabrata, a species often less susceptible to fluconazole, recent data suggest that switching to fluconazole is reasonable when susceptibility testing confirms the strain responds.⁶

Beyond the bloodstream, case reports have documented fluconazole treating Candida infections of bone and joints, the lining of the heart, the eye, and the abdominal cavity.⁷

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening brain infection caused by the fungus Cryptococcus neoformans, and it remains a leading killer of people living with advanced HIV, particularly in sub-Saharan Africa. Fluconazole plays two distinct roles here. In the acute treatment phase, high-dose fluconazole is used where the preferred drug, amphotericin B, is unavailable. A clinical trial found that weight-adjusted doses of 1,600 mg per day were safe and tolerable during the initial treatment of cryptococcal meningitis, and survival at that dose was not statistically different from amphotericin B. However, the lower World Health Organization-recommended dose of 1,200 mg per day was associated with poorer survival.⁸

Where fluconazole truly shines is in the maintenance phase. After the initial infection has been beaten back, the fungus tends to return unless patients take a suppressive antifungal long-term. A landmark placebo-controlled trial showed that fluconazole maintenance therapy cut the recurrence rate from 37 percent in the placebo group to just 3 percent in the fluconazole group over an average follow-up of about five and a half months.⁹ That finding made fluconazole the standard of care for preventing relapse in HIV-associated cryptococcal disease.

Why Fluconazole Reaches the Brain So Well

Most drugs have trouble getting past the blood-brain barrier, which is why brain infections are notoriously hard to treat. Fluconazole is an exception. In healthy volunteers receiving the drug intravenously, cerebrospinal fluid concentrations reached roughly 50 to 60 percent of blood levels.¹⁰ In patients with cryptococcal meningitis receiving higher oral doses, the ratio of drug exposure in cerebrospinal fluid to plasma averaged around 0.89, meaning the brain essentially sees almost as much drug as the blood does.¹¹ This excellent brain penetration is one of the main reasons fluconazole remains irreplaceable for fungal meningitis, even as newer antifungals have appeared for other indications.

Other Fungal Infections

Fluconazole is not limited to Candida and Cryptococcus. It is used for coccidioidomycosis, a lung and sometimes disseminated infection caused by the soil fungus Coccidioides (also known as valley fever). Fluconazole at 400 mg daily has been effective for various forms of the disease, including coccidioidal meningitis, though relapse after stopping therapy is a recognized problem.¹² For coccidioidal meningitis specifically, patients often remain on fluconazole indefinitely.

Fluconazole is also occasionally used for fungal nail infections (onychomycosis), though it is not the first choice. It is less effective than terbinafine and itraconazole for nails, but its once-weekly dosing schedule and relatively mild side-effect profile make it an option for people who cannot tolerate those alternatives.¹³

Preventing Fungal Infections in Vulnerable Patients

People with severely weakened immune systems, especially those undergoing bone marrow transplants or chemotherapy for blood cancers, are at high risk of developing invasive fungal infections. Fluconazole has been used as a preventive shield for these patients since the early 1990s. In a controlled trial of bone marrow transplant recipients, systemic fungal infections occurred in about 16 percent of patients receiving placebo compared with under 3 percent of those receiving fluconazole.¹⁴ Another study in patients with blood cancers found that those receiving fluconazole prophylaxis had significantly fewer clinically significant fungal infections and better survival compared with a topical antifungal regimen.¹⁵

One important caveat: fluconazole prophylaxis does not cover Aspergillus, a mold that causes a different kind of invasive fungal infection. In patients at high risk for aspergillosis, broader-spectrum antifungals like voriconazole or posaconazole are preferred. A study comparing prophylactic regimens did not find a significant difference in infection rates between fluconazole, voriconazole, and posaconazole, but the study was not powered to detect small differences and the patient populations differed in risk.¹⁶

Species That Do Not Respond

Fluconazole does not work equally well against all fungi, and this is one of the most clinically important things to understand about the drug. Candida krusei is considered intrinsically resistant, meaning it never responds to fluconazole. A systematic review and meta-analysis found pooled fluconazole resistance rates of about 78 percent in C. krusei, roughly 16 percent in C. glabrata, and around 13 percent in C. tropicalis.¹⁷ C. albicans, the most common cause of yeast infections, remains broadly susceptible, but resistance in non-albicans species has been rising steadily.

The mechanisms behind resistance vary. The most common route involves changes to the ERG11 gene, which codes for the very enzyme fluconazole targets. Mutations in this gene can alter the enzyme’s shape enough that fluconazole no longer binds to it effectively. In Candida tropicalis, specific ERG11 mutations have been linked to high resistance levels.¹⁸ Another strategy fungi employ is pumping the drug back out of the cell before it can do its work. In Candidozyma auris, a species that has drawn global alarm due to its multidrug resistance, roughly 95 percent of resistant isolates showed dramatically reduced fluconazole uptake, driven by mutations in multiple genes including ERG11 and drug-efflux pump regulators.¹⁹

Fluconazole also has no meaningful activity against molds like Aspergillus or the agents of mucormycosis. If a clinician suspects a mold infection rather than a yeast, fluconazole is simply the wrong drug.

Drug Interactions Worth Knowing About

Fluconazole is a potent inhibitor of certain liver enzymes that break down other medications. The most clinically dangerous interaction is with warfarin, the blood thinner. Fluconazole strongly inhibits the enzyme primarily responsible for clearing the active form of warfarin from the body, which can cause warfarin levels to spike and dramatically increase bleeding risk.²⁰ Anyone on warfarin who starts fluconazole needs closer monitoring of their clotting times.

The same enzyme-blocking property affects many other drugs. Certain diabetes medications, some anti-seizure drugs, immunosuppressants like cyclosporine and tacrolimus, and several heart-rhythm medications can all see their blood levels climb when fluconazole is added. At low single doses for a yeast infection, these interactions are usually brief and manageable. At higher doses given for weeks or months, the potential for harm is real and requires careful oversight.

Side Effects and Heart Rhythm Concerns

For most people taking a single dose or a short course, fluconazole is well tolerated. Common side effects are mild: nausea, headache, abdominal discomfort, and occasionally a rash. An analysis of adverse-event reports highlighted the importance of monitoring liver function, kidney function, and cardiovascular health during fluconazole treatment, particularly in high-risk patients.²¹

The most concerning adverse effect is QT prolongation, a change in the heart’s electrical cycle that can trigger a dangerous irregular rhythm called torsades de pointes. This risk increases at high doses, with prolonged use, and when fluconazole is combined with other drugs that also prolong the QT interval.²² Case reports of torsades de pointes in patients receiving high-dose fluconazole for serious fungal infections have been documented.²³ For the vast majority of patients taking a single 150-mg dose for a vaginal yeast infection, this is not a practical worry. For hospitalized patients on high doses, an electrocardiogram and electrolyte monitoring are standard precautions.

Fluconazole in Pregnancy

Pregnancy is one area where fluconazole use gets complicated. A large Danish study of over 7,000 fluconazole-exposed pregnancies found no overall increase in birth defects compared to unexposed pregnancies. However, it did find a roughly threefold increase in the risk of one specific heart defect, tetralogy of Fallot, though the absolute numbers were very small: 7 cases among exposed pregnancies versus an expected rate of about 3 per 10,000.²⁴ A meta-analysis pooling data from multiple studies found that first-trimester fluconazole exposure was associated with an increased prevalence of heart defects in the offspring at both low and higher doses.²⁵

Because of these findings, most guidelines now recommend topical antifungal treatments rather than oral fluconazole for vaginal yeast infections during pregnancy, especially in the first trimester. When a pregnant woman has a life-threatening systemic fungal infection and fluconazole is the best available drug, the risk-benefit calculation shifts, but the decision requires careful clinical judgment.

Dosing in Infants and Children

Premature infants in neonatal intensive care units are especially vulnerable to invasive Candida infections, and fluconazole is used both for prevention and treatment in this population. Dosing in young infants is tricky because their bodies process the drug differently than adults. Pharmacokinetic studies suggest that infants in the first 90 days of life need at least 12 mg per kilogram per day to achieve drug levels adequate for treating invasive candidiasis caused by susceptible species.²⁶ Loading doses, meaning a larger first dose to quickly reach effective levels, have also been studied. A single 25-mg-per-kilogram loading dose achieved the target drug exposure in most infants tested.²⁷

In older children, fluconazole dosing is more straightforward and typically follows weight-based guidelines similar to adults. Oral thrush, esophageal candidiasis in immunocompromised children, and urinary tract infections caused by yeast are among the common pediatric uses.

Use in Veterinary Medicine

Fluconazole is not just a human drug. Veterinarians prescribe it for dogs and cats with fungal infections, including blastomycosis, cryptococcosis, and Candida infections. A multi-institutional study of client-owned dogs and cats with naturally occurring fungal disease found that starting oral doses of 10 mg per kilogram twice daily in dogs, and 50 to 100 mg total daily in cats, were associated with steady-state drug levels linked to clinical remission.²⁸ The same properties that make fluconazole attractive in humans, oral availability, good tissue penetration, and a relatively mild side-effect profile, make it a practical choice for pet owners who need to administer medication at home over weeks or months.